150 related articles for article (PubMed ID: 35118587)
1. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
[TBL] [Abstract][Full Text] [Related]
2. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
[TBL] [Abstract][Full Text] [Related]
3. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
5. PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
Xiong L; Chen X; Liu N; Wang Z; Miao B; Gan W; Li D; Guo H
PLoS One; 2017; 12(9):e0185337. PubMed ID: 28949976
[TBL] [Abstract][Full Text] [Related]
6. PRCC-TFE3 regulates migration and invasion of translocation renal cell carcinomas via activation of Drp1-dependent mitochondrial fission.
Wang B; Gan W; Han X; Li D
Cell Biol Int; 2020 Aug; 44(8):1727-1733. PubMed ID: 32339358
[TBL] [Abstract][Full Text] [Related]
7. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
8. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
9. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
[TBL] [Abstract][Full Text] [Related]
10. TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
Damayanti NP; Cordova RA; Rupert C; Delle Fontane I; Shen L; Orsi S; Klunk AJ; Linehan WM; Staschke KA; Hollenhorst PC; Heppner DE; Pili R
Cancer Res; 2024 Apr; 84(8):1286-1302. PubMed ID: 38266162
[TBL] [Abstract][Full Text] [Related]
11. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
Classe M; Malouf GG; Su X; Yao H; Thompson EJ; Doss DJ; Grégoire V; Lenobin J; Fantoni JC; Sudour-Bonnange H; Khayat D; Aubert S; Tannir NM; Leroy X
Histopathology; 2017 Jun; 70(7):1089-1097. PubMed ID: 28106924
[TBL] [Abstract][Full Text] [Related]
12. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
[TBL] [Abstract][Full Text] [Related]
13. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
Neha ; Das P; Verma SP
Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
[TBL] [Abstract][Full Text] [Related]
14. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
15. The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC.
Wang B; Gan W; Han X; Liu N; Ma T; Li D
Int J Biol Macromol; 2021 Apr; 176():437-447. PubMed ID: 33592266
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
17. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis.
Prakasam G; Mishra A; Christie A; Miyata J; Carrillo D; Tcheuyap VT; Ye H; Do QN; Wang Y; Reig Torras O; Butti R; Zhong H; Gagan J; Jones KB; Carroll TJ; Modrusan Z; Durinck S; Requena-Komuro MC; Williams NS; Pedrosa I; Wang T; Rakheja D; Kapur P; Brugarolas J
J Clin Invest; 2024 Feb; 134(7):. PubMed ID: 38386415
[TBL] [Abstract][Full Text] [Related]
18. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
19. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods.
Lee HJ; Shin DH; Noh GY; Kim YK; Kim A; Shin N; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
Oncotarget; 2017 May; 8(19):30756-30765. PubMed ID: 28415646
[TBL] [Abstract][Full Text] [Related]
20. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
